Patents by Inventor Robert Teed

Robert Teed has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cystine knot peptides that bind alpha-V-beta-6 integrin
    Patent number: 9206237
    Abstract: Disclosed are peptides comprising a molecular scaffold portion and a loop portion that binds to integrin ?v?6. This integrin is expressed on pancreatic tumors, making the peptides useful as imaging agents, among other uses. The peptides showed single-digit nanomolar dissociation constants similar to antibodies used clinically for imaging and therapy. The peptides rapidly accumulated in ?v?6-positive tumors, which led to excellent tumor-to-normal contrast. The peptides are specific for the targeted integrin ?v?6 receptors expressed on orthotopic pancreatic tumors and various xenografts used. Additionally, pharmacokinetic-stabilization strategies endowed knots with rapid renal clearance, which significantly reduced off-target dosing.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: December 8, 2015
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Richard H. Kimura, Sanjiv S. Gambhir, Benjamin J. Hackel, Robert Teed, Bin Shen, Frederick T Chin, Zhen Cheng
  • CYSTINE KNOT PEPTIDES THAT BIND ALPHA-V-BETA-6 INTEGRIN
    Publication number: 20140271469
    Abstract: Disclosed are peptides comprising a molecular scaffold portion and a loop portion that binds to integrin ?v?6. This integrin is expressed on pancreatic tumors, making the peptides useful as imaging agents, among other uses. The peptides showed single-digit nanomolar dissociation constants similar to antibodies used clinically for imaging and therapy. The peptides rapidly accumulated in ?v?6-positive tumors, which led to excellent tumor-to-normal contrast. The peptides are specific for the targeted integrin ?v?6 receptors expressed on orthotopic pancreatic tumors and various xenografts used. Additionally, pharmacokinetic-stabilization strategies endowed knots with rapid renal clearance, which significantly reduced off-target dosing.
    Type: Application
    Filed: May 21, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Richard H. Kimura, Sanjiv S. Gambhir, Benjamin J. Hackel, Robert Teed, Bin Shen, Frederick T Chin, Zhen Cheng